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Abstract: Interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) are key cytokines 
that drive the production of inflammatory mediators and matrix-degrading enzymes in 
osteoarthritis (OA). These proinflammatory cytokines bind to their respective cell surface 
receptors and activate inflammatory signaling pathways culminating with the activation of 
nuclear factor κB (NF-κB), a transcription factor that can be triggered by a host of  
stress-related stimuli including, excessive mechanical stress and ECM degradation 
products. Once activated, NF-κB regulates the expression of many cytokines, chemokines, 
adhesion molecules, inflammatory mediators, and several matrix-degrading enzymes. 
Therefore, proinflammatory cytokines, their cell surface receptors, NF-κB and downstream 
signaling pathways are therapeutic targets in OA. This paper critically reviews the recent 
literature and outlines the potential prophylactic properties of plant-derived phytochemicals 
such as curcumin and resveratrol for targeting NF-κB signaling and inflammation in OA to 
determine whether these phytochemicals can be used as functional foods. 
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1. Introduction 
For the past 160 years human life expectancy has consistently increased by a quarter of a year every 
year [1]. The ―baby boom‖ generation born after World War II have now reached their mid- to late 60s. 
In many European countries one out of every five people is aged 65 and over. According to the 
Organization for Economic Co-operation and Development (OECD) [2], increases in life expectancy 
seen over the last few decades are likely to continue in the future. It is predicted that life expectancy 
will continue to increase by 2.5 years each decade, meaning that the western world’s average life 
expectancy should reach and exceed 100 within the next 50 years [1]. The increasing human life 
expectancy has resulted in an increase in the prevalence of several diseases. The main four chronic 
diseases that the ageing population will suffer from are: arthritis, heart problems, dementia, and 
diabetes. The growing burden of arthritic, rheumatic and musculoskeletal diseases will place an even 
greater socioeconomic burden on health systems around the world as the population ages. 
According to the World Health Organization (WHO) [3], orthopedic, rheumatic and musculoskeletal 
conditions comprise over 150 diseases and syndromes, which are usually progressive and associated 
with pain and disability. They can broadly be categorized as joint diseases, physical disability, spinal 
disorders, and conditions resulting from trauma. These conditions are leading causes of morbidity, 
giving rise to enormous healthcare expenditures and loss of productivity. Knowledge of the key 
determinants of disability in musculoskeletal conditions is critical for reducing their burden on the 
world’s growing population [1,4]. 
The United Nations, the WHO and 37 other countries have proclaimed the years 2000–2010 as the 
Bone and Joint Decade [3,5–7]. This global initiative is intended to improve the lives of people with 
musculoskeletal disorders, such as arthritis, and to advance understanding and treatment of 
musculoskeletal disorders through prevention, education and research. The 10 year global initiative 
launched by the UN urges governments around the world to start taking action to draw attention to the 
growing pervasiveness and impact of musculoskeletal diseases and to reduce the social and financial 
burdens to society. Support for this global initiative will raise awareness of musculoskeletal health, 
stimulate research and improve people’s quality of life. 
Musculoskeletal diseases are one of the major causes of disability around the world and have been a 
significant reason for the development of the Bone and Joint Decade [5–8]. Rheumatoid arthritis (RA), 
osteoarthritis (OA), gout and lower back pain are important causes of disability-adjusted-life years in 
both the developed and developing world [9]. 
OA is one of the most common types of arthritis [10–13]. It is a major cause of pain and disability 
in older individuals and is expected to place a heavy burden on healthcare systems around the world as 
the human population ages [14]. The incidence of OA is also expected to increase with the rise in 
obesity and metabolic diseases associated with being overweight [14–17]. It also affects older animals 
and has significant consequences for companion animal mobility and welfare [18]. OA is a 
Int. J. Mol. Sci. 2012, 13 4204 
 
 
degenerative disease of the whole joint [13] and involves synovial inflammation and the progressive 
and irreversible destruction of the extracellular matrix (ECM) of articular cartilage [10,19,20]. It is also 
characterized by subchondral bone sclerosis, synovial hyperplasia and osteophyte (bony outgrowth) 
formation [21]. OA can occur in any synovial joint but symptomatic OA in humans is most common in 
the knee [16]. Digits of the hand and the hip are also frequently affected. In general weight-bearing 
joints are the worst affected. The main risk factors for OA include age, gender, genetics, obesity, and 
joint injury or instability [17]. Cartilage damage in OA is detected radiographically by decreases in 
joint space width. However, radiographic evidence is seen only after significant cartilage degradation 
has already taken place. 
The major consequence of all forms of arthritis is joint dysfunction, disability, chronic pain, and 
significant morbidity. Aside from analgesics, there are currently no effective pharmacotherapies 
capable of restoring the structure and function of damaged synovial tissues in any form of arthritis. 
Consequently, there is an acute need for novel drugs and new therapies. In the following section we 
provide a brief overview of cartilage structure and function before discussing the molecular and 
cellular events that occur in a typical synovial joint in OA. 
2. Articular Cartilage-Structure and Function 
Cartilage is a flexible and mechanically compliant connective tissue found at the end of long bones 
in articulating joints and in the intervertebral disc. It is sub-classified into three different types: elastic 
cartilage, hyaline cartilage and fibrocartilage, which differ in the relative amounts of its three principal 
components, namely collagen fibers, ground substance (proteoglycans) and elastin fibers. Articular or 
hyaline cartilage is a load-bearing tissue with unique biological characteristics (Figure 1).  
Figure 1. Structure of human articular cartilage. This figure illustrates a sample of human 
cartilage from a tissue microarray developed by the Cooperative Human Tissue Network 
(CHTN) [22] of the National Cancer Institute [23]. Cartilage is predominantly an avascular, 
aneural and alymphatic load-bearing connective tissue consisting of a single cell type 
known as the chondrocyte. Blood vessels are only present in subchondral bone. 
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Its biochemical properties depend on the structural design of the tissue, the molecular composition 
of the ECM (Figure 2) that makes up the bulk of the tissue volume and the interactions between its 
resident cells and the ECM [24]. 
Figure 2. Molecular composition of the ECM of articular cartilage. The major collagenous 
and non-collagenous components of the territorial and interterritorial cartilage ECM are 
illustrated. 
 
Chondrocytes are the only cells found within the cartilage ECM. Cartilage is avascular, alymphatic 
and aneural. Nutrition is derived from synovial fluid (and for the deep zone by subchondral bone 
vessels). Chondrocytes are architects of cartilage [25], building the macromolecular framework of its 
ECM from three distinct classes of macromolecules: collagens (predominantly type II collagens), 
proteoglycans (mainly aggrecan), and a variety of non-collagenous proteins (Figure 2). Of the 
collagens present in articular cartilage collagens type II, IX, and XI form a fibrillar meshwork that 
gives cartilage tensile stiffness and strength [24,26,27], whereas collagen type VI forms part of the 
matrix immediately surrounding the chondrocytes, enabling them to attach to the macromolecular 
framework of the ECM and acting as a transducer of biomechanical and biochemical signals in the 
articular cartilage [28,29]. Large aggregating proteoglycans (aggrecan) are embedded in the collagen 
mesh and give cartilage its stiffness to compression, its resilience and contribute to its long-term 
durability [29–32]. 
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ECM proteins in cartilage are of great significance for the regulation of the cell behavior, 
proliferation, differentiation and morphogenesis [33–41]. Small proteoglycans, including decorin, 
biglycan, and fibromodulin are further embedded in the ECM. Decorin and fibromodulin both interact 
with the type II collagen fibrils in the matrix and have roles in fibrillogenesis and interfibril 
interactions. Biglycan is mainly found in the immediate surrounding of the chondrocytes, where it may 
interact with collagen type VI [24,29]. Modulation of the ECM proteins is regulated by the interaction 
of a diversity of growth factors with chondrocytes [42–46]. In fact, it has been reported recently, that 
IGF-I and TGF-β stimulate the chondrocyte surface expression of integrins, and that this event is 
accompanied by increasing adhesion of chondrocytes to matrix proteins [47]. Other non-collagenous 
proteins in articular cartilage such as cartilage oligomeric matrix protein (COMP) are less well studied 
and may have value as a biomarker of cartilage turnover and degeneration of [48], while tenascin and 
fibronectin influence interactions between the chondrocytes and the ECM [24,49]. The ECM surrounds 
chondrocytes; it protects them from the biomechanical stresses that occur during normal joint motion, 
determines the types and concentrations of molecules that reach the cells and helps to maintain the 
chondrocyte phenotype. 
Throughout life, cartilage is continually remodeled as chondrocytes replace matrix macromolecules 
lost through degradation. Evidence indicates that ECM turnover depends on the ability of chondrocytes 
to detect alterations in the macromolecular composition and organization of the matrix, such as the 
presence of degraded macromolecules, and to respond by synthesizing appropriate types and amounts 
of new ECM components. It is known that mechanical loading of cartilage creates mechanical, 
electrical, and physicochemical signals that help to direct the synthesizing and degrading activity of 
chondrocytes [50]. In addition, the ECM acts as a signal transducer for chondrocytes [51]. A prolonged 
and severe decrease in the use of the joint leads to alterations in the composition of the ECM and 
eventually to a loss of tissue structure and its specific biomechanical properties, whereas normal 
physical strain stimulates the synthesizing activity of chondrocytes and possibly internal tissue 
remodeling [52,53]. 
Although articular cartilage can tolerate a tremendous amount of intensive and repetitive physical 
stress, it manifests a striking inability to heal even the most minor injury [52,54–56]. This makes joints 
particularly sensitive to degenerative processes [57]. Furthermore, aging leads to alterations in ECM 
composition and alters the activity of chondrocytes, including their ability to respond to a variety of 
stimuli such as growth factors [58–60]. All these alterations increase the probability of cartilage 
degeneration [55,61–63] and emphasize the importance of interaction of chondrocytes with their 
surrounding ECM since this interaction regulates their growth, differentiation, and survival [64]. 
3. Articular Cartilage Degradation in OA 
OA (also known as osteoarthrosis or degenerative joint disease) is one of the most prevalent and 
chronic diseases affecting the elderly [65]. The symptoms and signs characteristic of OA in the most 
frequently affected joints are heat, swelling, pain, stiffness and limited mobility. OA is often a 
progressive and disabling disease, which occurs in the setting of a variety of risk factors, such as 
advancing age, obesity, and trauma, that conspire to incite a cascade of pathophysiological events 
within joint tissues [66]. Other sequelae include osteophyte formation and synovitis [13]. These 
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manifestations are highly variable, depending on joint location and disease severity. Other forms of 
arthritis include psoriatic arthritis, and autoimmune diseases in which the body’s immune system 
attacks itself such as RA. Discussing these diseases in detail is beyond the scope of this review. Figure 
3 outlines the major molecular and cellular changes that occur in the synovial joint in OA. 
Figure 3. Summary of the major molecular and cellular changes that occur in the synovial 
joint during inflammation in OA. Summary of the major synovial, chondral and 
subchondral changes observed in OA. This schematic also highlights the actions of various 
white blood cells and inflammatory mediators in OA. Chondral changes include cartilage 
fragmentation (fibrillation), cartilage degradation and loss of collagen type II and 
glycosaminoglycans, chondrocyte apoptosis (hypocellularity) and matrix mineralization. 
Synovial membrane changes in OA include inflammation, synovial hypertrophy, 
recruitment and activation of T cells, macrophages and fibroblasts, production of matrix 
metalloproteinases (MMPs) and reactive oxygen species (ROS). Synovial fluid alterations 
in OA include accumulation of MMPs and ROS, release of IL-1β, TNF-α and other 
proinflammatory cytokines (IL-6, IL-8), release of inflammatory pain mediators such as 
prostaglandin E2 (PGE2), formation of degradative products and microcrystals. 
Subchondral alterations in OA include subchondral sclerosis (i.e., eburnation), osteoblast 
mediated subchondral bone formation, proteolysis (degradation) of IGF-I and IGF-I 
binding proteins, increased production of some growth factors and cytokines including: 
transforming growth factor β, TGF-β, PGE2; interleukin 6, IL-6 and IGF-I. 
 
OA can affect any synovial joint but it primarily affects large load-bearing joints such as the hip and 
knee. The disease is essentially one acquired from daily wear and tear of the joint. Its most prominent 
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feature is the progressive destruction of articular cartilage [11]. OA begins in articular cartilage and 
eventually spreads to other synovial tissues. The current consensus is that OA is a disease involving 
not only articular cartilage but also the synovial membrane, subchondral bone and peri-articular soft 
tissues [67]. OA may occur following traumatic injury to the joint, subsequent to an infection of the 
joint or simply as a result of aging and the mechanical stresses associated with daily life. 
It is now generally accepted that OA must be viewed not only as the final common pathway for 
aging and injuries of the joint, but also as an active and inflammatory joint disease. As medical 
advances lengthen average life expectancy, OA will become an even larger public health  
problem—not only because it is a manifestation of aging but because it usually takes many years to 
reach clinical relevance. OA is already one of the ten most disabling diseases in industrialized 
countries. It is one of the most prevalent and chronic diseases affecting the elderly [65]. OA is rare in 
people under 40 but becomes more common with age—most people over 65 years of age show some 
radiographic evidence of OA in at least one or more joints. OA is the most frequent cause of physical 
disability among older adults globally. According to the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases (NIAMS) more than 20 million Americans are estimated to  
have OA [68]. It is also anticipated that by the year 2030, 20% of adults will have developed OA in 
Western Europe and North America. Statistical data from epidemiological studies in North America 
and Australia suggest that arthritis is the number one condition associated with functional limitation 
and physical disability among US population aged 65 and older and affects 30% of the population [69]. 
The data from the 2003 Survey of Disability, Ageing and Carers in Australia [70] suggests that the 
percentage of older people with OA is even higher—around 50% profoundly and severely effecting 
their core activity and limiting their mobility. The reported prevalence of arthritis and its associated 
risk factors (i.e., obesity and metabolic disease) has also increased among people aged 65 and over in 
nearly all European member states. 
The symptoms and signs characteristic of OA in the most frequently affected joints are heat, 
swelling, pain, stiffness and limited mobility. OA is often a progressive and disabling disease, which 
occurs in the setting of a variety of risk factors, such as advancing age, obesity, and trauma, that 
conspire to incite a cascade of pathophysiological events within joint tissues [66]. Other important 
sequelae include osteophyte formation, inflammation of the synovial membrane (synovitis) and joint 
swelling [13]. These manifestations are highly variable, depending on joint location and disease 
severity. Other forms of arthritis include psoriatic arthritis, and autoimmune diseases in which the 
body’s immune system attacks itself such as RA. The synovitis that occurs in both the early and late 
phases of OA is associated with alterations in the adjacent cartilage. Catabolic and proinflammatory 
mediators such as cytokines, nitric oxide, prostaglandin E2 (PGE2) and neuropeptides are produced by 
the inflamed synovium and alter the balance of cartilage matrix degradation and repair, leading to 
excess production of the proteolytic enzymes responsible for cartilage breakdown [71]. Cartilage 
alterations induce further synovial inflammation, creating a vicious circle and the progressing synovitis 
exacerbates clinical symptoms and stimulates further joint degradation in OA [71]. Figure 3 outlines 
the major molecular and cellular changes that occur in the synovial joint in arthritis and synovitis. 
OA, is an important cause of disability-adjusted-life years in both the developed and developing 
world [9]. Until recently OA was viewed as a ―degenerative‖ or ―wear-and-tear‖ disease and held little 
interest for most clinicians. It is now accepted that the age-related degeneration of articular cartilage as 
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part of the clinical syndrome of OA is one of the most common causes of pain and disability in middle-
aged and older people [9]. OA is the most common form of joint disease, with the majority of the 
population over 65 years of age demonstrating radiographic evidence of OA in at least one joint.  
4. Cytokines and OA 
Cytokines are signaling molecules and major mediators of inflammatory responses. They are small 
proteins and signaling molecules produced by a variety of different cell types. They control many 
different cellular functions including proliferation, differentiation and cell survival/apoptosis. They 
play essential an indispensable roles in cell signaling and communication and possess potent 
immunomodulatory properties. They are also involved in a plethora of pathophysiological processes 
including viral infections, autoimmune diseases, arthritis and cancer. Cytokines are synthesized under 
various stimuli by a variety of cells of both the innate (monocytes, macrophages, dendritic cells) and 
adaptive (T- and B-cells) immune systems. They have been classed as lymphokines, interleukins, and 
chemokines, based on their functions. The term ―interleukin‖ was initially used by researchers for 
those cytokines whose presumed targets are principally leukocytes. The term ―chemokine‖ refers to a 
specific class of cytokines that mediates chemo-attraction (chemotaxis) between cells. In many 
publications cytokines are listed along with hematopoietic growth factors, interferons, lymphokines, 
monokines, chemokines, and other cytokines [72]. Cytokines can be classified into two groups: 
proinflammatory and anti-inflammatory. Proinflammatory cytokines, including IFN-γ, IL-1β, IL-6 and 
TNF-α, are predominantly derived from the innate immune cells and Th1 cells. Anti-inflammatory 
cytokines, including IL-10, IL-4, IL-13 and IL-5, are synthesized from Th2 immune cells. The role of 
proinflammatory cytokines in RA is very well established [73]. Anti-cytokine therapy for RA has 
become a clinical treatment for aggressive forms of the disease [74]. However, proinflammatory 
cytokines also contribute to the pathogenesis of OA. The disease is strongly linked to aging; cell stress, 
injury or damage in response to chronic inflammation and exposure to cytokines, chemokines, and 
proteases is thought to drive its progression [75]. 
5. The Role of Cytokines in Arthritis 
It is now generally accepted that proinflammatory cytokines are pleiotropic contributors to synovial 
joint pathology in OA and RA. In the following sections we discuss the principal cytokines involved in 
the pathogenesis of OA and its progression. Many studies have demonstrated the involvement of 
cytokines in the pathogenesis of OA (Figure 3). They are involved with synovial membrane, cartilage 
and bone changes in the disease process. It is now thought that much of the cytokine expression is 
initially by the synovium, predominantly from the synovial macrophages, which drive the 
inflammatory and destructive responses in OA [76]. These cytokines are thought to diffuse through the 
synovial fluid into the cartilage where they stimulate the chondrocytes and synoviocytes to synthesize 
further cytokines as well as degradative proteases. The intimal cells of the synovium are most 
significant in the production of cytokines that cause inflammation [77]. The main proinflammatory 
cytokines thought to be involved in the pathogenesis of OA are Tumor Necrosis Factor α (TNF-α) and 
Interleukin-1 β (IL-1β) which act on synoviocytes and chondrocytes through specific interactions with 
cytokine receptors on the cell surface. The receptors thought to be involved in OA are the  
Int. J. Mol. Sci. 2012, 13 4210 
 
 
IL-1β receptor, IL-1R type I, and the TNF-α receptor, TNF-R55, due to their elevated expression in 
OA human synovial fibroblasts [78,79]. 
There are also other proinflammatory cytokines produced by the synovium and involved in the OA 
disease process to a lesser extent. The effects of the proinflammatory cytokines on cartilage are shown 
in Table 1. 
Table 1. Proinflammatory cytokines involved in OA. 
Cytokine Expression  Functions References 
TNF-α Synoviocytes 
Chondrocytes 
Increase cartilage degradation and bone 
resorption 
 [80,81] 
Inhibit glycoprotein and collagen synthesis.  [82] 
Upregulate MMP expression  [83] 
Stimulate other cells to produce 
proinflammatory cytokines and growth 
factors 
 [84] 
Stimulate proangiogenic factor release  [85] 
Stimulate other cells to produce chemotactic 
cytokines 
 [86,87] 
Stimulate Nitric Oxide (NO) production  [88] 




Increase cartilage degradation and bone 
resorption 
 [80,81,90] 
Inhibit proteoglycan synthesis  [91,92] 
Upregulate MMP expression  [93] 
Production of proteolytic enzymes   [94] 
Stimulate other cells to produce 
proinflammatory cytokines 
 [77] 
Stimulate other cells to produce chemotactic 
cytokines 
 [86,87] 
Stimulate proangiogenic factor release  [85] 
Stimulate NO production  [95] 







Inhibit proteoglycan synthesis   [96] 
Reduce chondrocyte proliferation  [96] 
Increase MMP-2 activity  [97] 
Increase aggrecanase-mediated proteoglycan 
catabolism 
 [98] 
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Table 1. Cont. 





Recruits leucocytes  [99] 
Neutrophil chemoattractant  [100] 
Stimulates release of proinflammatory 
cytokines 
 [101] 
Hypertrophic differentiation and calcification 
of chondrocytes 
 [102] 
IL-17 Activated  
T-lymphocytes 
Induce NO synthesis  [103,104] 
Induce MMP synthesis  [103,104] 
Increase production of IL-1β, Il-6 and IL-8  [103,105] 




Stimulate release of proinflammatory 
cytokines 
 [107,108] 
Stimulate angiogenesis  [109] 
Induce NO synthesis  [108] 
Synovial hyperplasia and inflammatory cell 
recruitment 
 [110] 
Induce chondrocyte apoptosis  [111] 
Reduce expression of cartilage matrix 
components 
 [111] 









Stimulate proinflammatory cytokine 
expression 
 [112,113] 
Increase pro-MMP-2 synthesis  [97] 
Increase MMP-13 synthesis and activity  [114] 
Increase cartilage resorption  [115] 
Decrease proteoglycan synthesis  [116] 
Leukocyte infiltration into synovial fluid  [117] 
Increase cartilage degradation when in 
combination with IL-1β and TNF-α 
 [115] 
6. NF-κB Signaling in Arthritis 
The activation of NF-κB (nuclear factor-κB) transduction pathway has been linked with a variety of 
inflammatory diseases, including cancer, atherosclerosis, myocardial infarction, diabetes, allergy, 
asthma, arthritis, Crohn’s disease, multiple sclerosis, Alzheimer's disease, osteoporosis, psoriasis, 
septic shock, and AIDS [118,119]. As an activator of many pro-inflammatory cytokines and 
inflammatory processes NF-κB is a principal target to alleviate the symptoms of such inflammatory 
diseases [120]. NF-κB is a rapidly acting primary transcription factor found in all cell types. It is 
involved in cellular responses to proinflammatory stimuli such as cytokines and stress and plays a key 
role in regulating the immune response to infection. NF-κB can be triggered by a host of stress-related 
stimuli including proinflammatory cytokines, excessive mechanical stress and ECM degradation 
products [121]. In unstimulated cells NF-κB dimers are sequestered inactively in the cytoplasm by a 
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protein complex called inhibitor of κB (IκB). IκB inactivates NF-κB by masking the nuclear 
localization signals (NLS). Activation of NF-κB occurs via degradation of IκB, a process that is 
initiated by its phosphorylation by IκB kinase (IKK). Phosphorylated IκB becomes dissociated from 
NF-κB, unmasking the NLS. Phosphorylation also results in IκB ubiquitination and targeting to the 
proteasome. NF-κB can now enter the nucleus and regulate gene expression. NF-κB turns on 
expression of IκB forming a negative feedback loop. Targeted strategies to prevent unwanted or 
excessive NF-κB activation are the focus of current research. Work in this area is focused on the use of 
highly specific drug modalities, siRNAs or other biological inhibitors [121]. Further work is needed to 
evaluate the effects of efficacious, targeted NF-κB inhibitors in animal models of OA disease in vivo 
and to also target these strategies only to affected cartilage and joints to avoid other undesirable 
systemic effects [121]. 
Recent research has shown that the pathway that activates NF-κB can be interrupted or functionally 
modulated by naturally occurring phytochemicals derived from spices such as curcumin, capsaicin, 
eugenol, gingerol, anethol, ursolic acid, diallyl sulfide, S-allylmercaptocysteine, ajoene, and ellagic 
acid [118]. 
7. Curcumin and Resveratrol—Naturally Occurring NF-κB Inhibitors 
Current treatments for OA and gut are associated with unwanted side effects and are expensive. 
Natural products do not have such disadvantages, offer alternative treatment options for OA [122,123]. 
Traditional and complementary medicine is known to be fertile ground for the source of modern 
medicines [124]. In many different chronic diseases (including OA) in which inflammation is known 
to play a central role, plant derived phytochemicals (i.e., curcumin and resveratrol) have been shown to 
exhibit therapeutic potential. The main aim of OA therapy is to counteract the local chronic 
inflammation, associated inflammatory symptoms in the joints, delay joint degradation, reduce and 
minimize disability and provide a better quality of life for patients. It is recognized that current 
treatments for arthritis are inefficient, cause substantial side effects, and tend to be expensive 
(especially when the is cost of treatment is calculated and spread over the long time course of the 
disease). However, natural products do not have such disadvantages and offer novel and 
complementary treatment opportunities [122,123]. A number of natural substances have been 
investigated for their anti-inflammatory capabilities, including omega-3 fatty acids (FA) [125],  
curcumin [126], resveratrol [127], the polyphenolic green tea catechins [128,129], and various 
flavonoids [130,131]. Many of them have the ability to interfere with inflammatory processes and their 
mediators. Thus their use along with NSAIDs may reduce inflammation and damage to joint tissues 
and could be of prophylactic and therapeutic value. Therefore, naturally occurring compounds capable 
of blocking NF-κB mediated catabolic activity may prove to be promising therapeutic agents for the 
treatment of OA and other inflammatory conditions. This realization has resulted in the proliferation of 
new research aimed at understanding how nutrients and genes interact. This new field is known as 
nutrigenomics and this paper’s focus on curcumin and resveratrol and many other studies in the 
literature highlight how these compounds target transcription factors such as NF-κB, AP-1, Egr-1, 
STATs, PPAR-γ, β-catenin, nrf2, EpRE, p53, CBP, and androgen receptor (AR) and AR-related 
cofactors [132]. 




Curcuma longa or turmeric is a tropical plant native to south and southeast tropical Asia. It is a 
member of the ginger family (Zingiberaceae) and is one of the most important of the Indian spices. 
Curcumin (diferuloyl methane) is the principal curcuminoid and the most active component in turmeric. 
It may make up 2–5% of the total spice in turmeric. Commercial curcumin contains three major 
components: diferuloylmethane (82%), demethoxycurcumin (15%) and bisdemethoxycurcumin (3%), 
together referred to as curcuminoids [133], all of which have anti-inflammatory activity. Turmeric has 
been used in Ayurvedic Medicine (traditional Indian medicine) for thousands of years to treat various 
common diseases including gastrointestinal diseases (i.e., stomach ulcers), jaundice, arthritis, wounds 
and skin and eye infections [134–136]. Preclinical and clinical studies have shown that curcumin has 
potential therapeutic value against most chronic diseases including neoplastic, neurological, 
cardiovascular, pulmonary, metabolic and arthritic diseases. Several recent studies have also shown 
that curcumin has potential for the complementary treatment of arthritis [137,138]. 
The first preliminary study on the anti-rheumatic activity of curcumin was published in 1980. 
Unfortunately, this study was fundamentally flawed because of the lack of appropriate controls [139]. 
Studies in a rat model of joint inflammation showed that oral administration of capsaicin and curcumin 
lowered the levels of paw inflammation [140]. In early 2000 work on synovial fibroblasts derived from 
RA patients showed that curcumin inhibits the macrophage migration inhibitory factor (MIF) induced 
up-regulation of matrix metalloproteinases MMP-1 (interstitial collagenase) and MMP-3  
(stromelysin) [141]. Curcumin strongly inhibits collagenase and stromelysin expression at micromolar 
concentrations [142]. Curcumin is actually a potent inhibitor of MIF [143]. Curcumin is a potent 
inhibitor of the production of inflammatory and catabolic mediators by chondrocytes, suggesting that 
this natural compound could be efficient in the treatment of OA [144]. Curcumin can induce apoptosis 
and inhibit prostaglandin E(2) (PGE2) production in synovial fibroblasts of patients with RA, 
suggesting that curcumin might be used to control hyperplasia of the synovial fibroblasts in RA [145].  
In chondrocytes curcumin was shown to suppress oncostatin M (OSM) stimulated STAT1 
phosphorylation, DNA-binding activity of STAT1, and c-Jun N-terminal kinase activation as well as 
inhibiting OSM-induced MMP-1, MMP-3, MMP-13, and TIMP-3 gene expression [146]. Curcumin 
was also shown to induce a 48–99% suppression of MMP-3 and 45–97% downregulation of  
MMP-13 in human chondrocytes and 8–100% (MMP-3) and 32–100% (MMP-13) in bovine 
chondrocytes [147]. Curcumin was also shown to suppress TNF-α-induced MMP-13 expression in 
primary chondrocytes and SW1353 chondrosarcoma cells [135]. 
Work from our laboratories has demonstrated some of the protective and anti-inflammatory effects 
of curcumin using biochemical and morphological techniques. To test the hypothesis that curcumin 
protects chondrocytes from morphological alterations induced by IL-1β, we investigated its in vitro 
effects on apoptotic signaling proteins and key cartilage-specific matrix components in  
IL-1β-stimulated chondrocytes. Transmission electron microscopy was employed to demonstrate that 
curcumin inhibits the early degenerative changes induced by IL-1β [148]. Additionally, curcumin 
antagonized the suppression of collagen type II and β1-integrin synthesis and caspase-3 activation 
induced by IL-1β was inhibited by curcumin [148]. This study clearly demonstrated that curcumin 
exerts anti-apoptotic and anti-catabolic effects on IL-1β-stimulated articular chondrocytes and may 
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have novel therapeutic potential for treating OA and related osteoarticular diseases [148]. We used an 
explant model of cartilage inflammation to demonstrate that IL-1β-induced ECM degradation and 
glycosaminoglycan release can be inhibited by curcumin [13]. 
Curcumin appears to exert its anti-inflammatory effects in a ―concentration-dependent‖ or  
―dose-dependent‖ manner. Studies on RA-derived synovial fibroblasts have shown that curcumin  
dose-dependently abrogates the effect of IL-18 on VEGF production [149]. Interestingly, a study on 
biological activities of turmeric extract has shown that the three major curcuminoids in turmeric are 
responsible for its anti-arthritic effects while the remaining compounds in crude turmeric extracts may 
actually inhibit its anti-inflammatory and protective effects [150]. Studies on other curcuma plants 
have shown that there is a possible curcuminoid-independent pathway mediated by  
curcuma phaeocaulis extract [151]. Further studies are required to corroborate these findings. 
Treatment of chondrocytes with curcumin suppresses IL-1β-induced NF-κB activation via 
inhibition of IκBα phosphorylation, IκBα degradation, p65 phosphorylation and p65 nuclear 
translocation [152]. Curcumin also inhibits the IL-1β-induced stimulation of up-stream protein kinase 
B Akt, molecular events that correlate with down-regulation of NF-κB targets including COX-2  
and MMP-9 [152]. 
Curcumin is also able to antagonize the IL-1β and TNF-α-dependent up-regulation of MMPs and 
COX-2. Curcumin has been shown to inhibit the inflammatory and apoptotic effects of IL-1β on 
chondrocytes and this correlates with down-regulation of NF-κB-specific gene products that are known 
to mediate inflammation, degradation and apoptosis of chondrocytes in OA. Additionally, both 
curcumin suppressed IL-1β-induced down regulation of the cartilage specific ECM component 
collagen type II and of the cartilage specific master transcription factor Sox-9. Furthermore, inhibition 
of NF-κB activation by curcumin occurs mainly through the IKK inhibition [135,138,141,152]. 
When considering the biological effects of curcumin in cartilage and synovial cells and joint tissues, 
the overriding question is whether curcumin is safe. The research conducted to date with curcumin 
suggests that it has a good safety record. However, this is not supported by clinical evidence and data 
from clinical trials. Another important and largely neglected issue is the bioavailability of curcumin 
and curcuminoids, which is poor generally. Enhancing the bioavailability of curcumin is an important 
and goal and is likely to bring this promising natural product to the forefront of therapeutic agents for 
treatment of human diseases [153]. Curcumin is also a powerful inhibitor of inflammatory pathways 
and mediators. The schematic shown in Figure 4 summarizes the available information in PubMed on 
the effects of curcumin on the TNF-α receptor and its downstream signaling pathway.  
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Figure 4. Schematic of the effects of curcumin on the TNF-α receptor and its downstream 
signaling pathway. The biochemical pathway illustrated here was generated by text mining 
and makes use of a collection of canonical Ariadne pathways in addition to MedScan  
text mining. 
 
Its anti-catabolic effects, namely reducing degradative enzyme expression and activity, and its 
positive influence on anabolic gene expression suggests that it may be a suitable adjunct to 
conventional pharmaceutical (i.e., NSAID) therapy. The available information suggests that curcumin 
could be an alternative to NSAIDs. In contrast to NSAIDs, curcumin has no gastrointestinal side 
effects, and can even protect the gastric mucosa. Therefore, curcumin could be beneficial in the 
management of chronic inflammatory-related joint disease, including OA. However, despite this 
optimistic view, it must be recognized that there is still a paucity of data regarding possible adverse 
effects of curcumin at concentrations that are biologically effective in vitro. Indeed, the absence of 
systemic adverse effects after oral administration of curcumin is probably the result of its poor 
bioavailability and chemical modification by the gut and liver. Whilst some evidence exists for toxicity, 
at super-physiological concentrations, these are unlikely to be experienced or achieved in vivo. 
Nevertheless, we cannot exclude the possibility that increasing curcumin absorption, by chemical or 
natural process, could have unsuspected deleterious effects. It is now documented that curcumin at 
concentrations in excess of 50 mM shows cytotoxicity in a chondrocyte cell line [154]. The relevance 
of this toxicity in in vitro models is highly questionable. Nevertheless, the long-term effects of 
curcumin have not been studied and there is no published information about the possible side effects of 
the metabolites of curcumin. Further work is therefore required to address the issues of bioavailability 
and tissue accumulation in order to calculate appropriate dose formulations to assess whether curcumin 
Int. J. Mol. Sci. 2012, 13 4216 
 
 
can be convincingly considered as an aid to treating OA. Curcumin regulates inflammatory cytokines 
such as IL-1β, IL-6, IL-12, TNF-α and IFN-γ and associated JAK-STAT, AP-1, and NF-κB signaling 
pathways in immune and connective tissue cells [155]. 
9. Clinical Trials of Curcumin 
There are currently no registered clinical trials of curcumin in OA. ―Curcumin in Rheumatoid 
Arthritis‖ (ClinicalTrials.gov [156] Identifier: NCT00752154 [157]) is a clinical trial registered on the 
Clinical Trials database. The study is sponsored by University of California at Los Angeles. It is a 
randomized, placebo-controlled crossover study in which 40 subjects will receive a total of 4 g of 
curcumin per day (capsule form, precise composition not disclosed) and then switch to placebo.  
The subjects’ participation may last up to 8 months. By completion of the study, all 40 subjects will 
have taken curcumin and placebo for 4 months each. Subjects will have blood tests, complete 
questionnaires, and be seen by the study doctor. At the present time status of this study is unknown and 
it looks like the original completion deadline will not be met. However, when the study is completed it 
will be very interesting to see if curcumin has provided any benefits for RA patients. 
10. Bioavailability and Topical Delivery of Curcumin 
The major problem associated with the use of curcumin as a drug is its low bioavailability. A recent 
study has attempted to enhance the bioavailability of curcumin by complexation with phosphatidyl 
choline followed by pharmacokinetic studies in rats [158]. The complex was shown to have 
significantly increased absorption compared with curcumin, when given in equimolar doses. The 
complex also showed enhanced bioavailability, improved pharmacokinetics, and increased 
hepatoprotective activity as compared with curcumin [158]. The authors have proposed that the 
enhanced bioavailability of the complex may be due to its amphiphilic nature, which greatly enhance 
the water and lipid solubility of the curcumin. This study opens up new opportunities for enhancing the 
absorption and bioavailability, and pharmacokinetics of curcumin. Several companies have already 
started selling products combining curcumin with phosphatidyl choline for improved absorption. 
Another area of interest is enhancing the topical delivery of curcumin [159]. This approach is 
intended to increase the absorption of curcumin through skin. Combinations of cyclodextrins and 
alginates were used in a study by Hegge and colleagues to solubilize curcumin in aqueous  
vehicles intended for topical delivery [160]. The study concluded that a combination of  
hydroxypropyl-β-cyclodextrin and propylene glycol alginate enhances curcumin solubility and release 
from the vehicle [160]. These studies have demonstrated the importance of optimizing the solvent 
systems when utilizing cyclodextrins as drug carriers for topical treatments [159,160]. 
11. Synergistic Effects of Curcumin and NSAIDs 
There is increasing interest in using curcumin in conjunction with NSAIDs to reduce the dosage of 
NSAIDs. Banerjee et al., (2003) used an adjuvant model of rat inflammation to demonstrate that 
curcumin and ibuprofen modulate inflammatory biomarkers such as C-reactive protein when used in 
combination [161]. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic 
Int. J. Mol. Sci. 2012, 13 4217 
 
 
effects of the NSAID celecoxib in OA-derived synovial adherent cells [162]. This was one of the first 
studies to show that synergistic effects of curcumin and celecoxib may enable the use of celecoxib at 
lower and safer concentrations [162]. Evaluation of the effects of celecoxib and curcumin in patients 
with OA is ongoing in human clinical trials [163]. Synergistic action of curcumin and conventional 
NSAIDs is an interesting concept and may pave the way for a novel combination treatment in OA and 
other rheumatologic disorders [162]. Ongoing clinical trials should provide a deeper understanding of 
the mechanisms and therapeutic potential of curcumin [164]. 
12. Resveratrol 
Resveratrol or trans-3,5,4'-trihydroxystibene is a polyphenolic, antifungal natural phytoalexin found 
in grapevines (Vitis vinifera) and a variety of other plants. It is found in the vines, roots, seeds and 
stalks, but its highest concentration is in grape skins. Resveratrol has been shown to possess potent 
anti-inflammatory, antioxidant and anticancer properties. It has been studied because of its  
anti-carcinogenic, anti-inflammatory and cardioprotective properties (coronary artery protection 
cumulating in the so called ―French Paradox‖) [165]. In addition resveratrol is thought to as suppresses 
angiogenesis and prevent diabetes mellitus. There are also suggestions that it may prolong  
lifespan [166–168]. Since resveratrol is a potent and specific inhibitor of cytokine-induced NF-κB 
activation, it may have potential for treating OA [137,138,143,169,170]. 
Studies in the rat suggest that resveratrol is absorbed in the duodenum. However,  
resveratrol-glucuronide was the major form absorbed when compared to the minute amounts of 
unconjugated resveratrol and resveratrol-sulfate [171]. Resveratrol is glucuronated in the liver  
and sulfated in both the liver and the duodenum [172]. The major derivatives of resveratrol 
glucuronidation are trans-resveratrol-3-O-glucuronide, trans-resveratrol-4'-O-glucuronide, and  
trans-resveratrol-3-O-sulfate [173]. Therefore, resveratrol exhibits numerous different mechanisms of 
action and targets are great number of intracellular molecules.  
13. Resveratrol and Transcription factor NF-κB 
As discussed earlier many inflammatory factors involved in arthritis, are regulated by the 
transcription factor Nuclear Factor-κB (NF-κB) [174]. NF-κB regulates many important signaling 
pathways in diseases with an inflammatory component [175–177]. Resveratrol blocks TNF-α-induced 
activation of NF-κB and suppresses TNF-α-induced phosphorylation and nuclear translocation of the 
p65 subunit of NF-κB and NF-κB-dependent reporter gene transcription [178]. 
Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenases. Lipoxygenases are 
dioxygenases with peroxidase activity involved in the synthesis of mediators for inflammatory, 
atherosclerotic, and carcinogenic processes. Additionally resveratrol can inhibit lipoxygenases through 
being oxidized by their peroxidase activity. Resveratrol and its oxidized form can act as inhibitors of 
the dioxygenase activity of lipoxygenase [179]. 
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14. Resveratrol and OA 
The phenomena that inflammatory cytokines such as IL-1β and TNF-α stimulate matrix degrading 
enzymes such as matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2), through 
activation of NF-κB, leading to cartilage matrix destruction, joint inflammation and play an important 
part in pathogenesis of RA and OA [152]. COX-2 activation stimulates prostaglandin production 
mediating inflammation [180]. The classical treatment for OA and RA is with COX inhibitors. 
However, NSAIDs have well known and severe side effects such as gastric ulcerations and do not 
inhibit the production of inflammatory stimulating mediators. Thus, degradation of joint cartilage is 
further promoted. This is why there is an emerged request for anti-inflammatory treatment that on one 
hand inhibits COX-2 (and thus prostaglandin production) but on the other hand further block the 
continuing joint degeneration. Interestingly, Subbaramaiah and co-workers have demonstrated that 
resveratrol has COX-2 inhibitory effects. The addition of pure resveratrol inhibited COX-2 expression 
and the production of prostaglandin E2 [181]. Furthermore, Elmali et al. demonstrated that intra-articular 
injections of resveratrol in rabbit inflammatory arthritis model had a chondroprotective effect on the 
cartilage [169,182]. We have shown that resveratrol has anti-apoptotic effects on primary chondrocytes 
by inhibiting the IL-1β-induced stimulation of caspase-3 and the cleavage of the DNA repair enzyme 
poly(ADP-ribose)polymerase (PARP) in human articular chondrocytes [183]. Furthermore, we have 
demonstrated that resveratrol inhibits the cysteine protease caspase-3 and the subsequent cleavage of 
the DNA repair enzyme PARP and the IL-1β-induced up-regulation of reactive oxygen species (ROS) 
in chondrocytes [137].  
In vitro studies have shown that IL-1β-induced suppression of chondrocyte proliferation and 
morphological alterations are suppressed by resveratrol. Resveratrol inhibits membrane-bound IL-1β 
and mature IL-1β protein production in chondrocytes. Furthermore, co-treatment of IL-1β-stimulated 
cells with resveratrol blocks activation of caspase-3, PARP cleavage, apoptosis and accumulation of 
tumor suppressor gene protein p53 and induces ubiquitin-independent degradation of p53. Resveratrol 
suppresses IL-1β-induced, NF-κB-dependent proinflammatory and matrix degrading gene products 
including MMPs, caspase-3, VEGF and COX-2. Resveratrol inhibits IL-1β-induced IκB-α degradation 
and consequently accumulated IL-1β-induced IkB-α phosphorylation. Resveratrol suppressed  
IL-1β-induced NF-κB dependent expression of apoptosis-related gene products by the accumulation of 
phosphorylated IκB-α, ubiquitinated IκB-α and inhibition of proteasome activity [137,138,183,184]. 
The in vivo effects of intra-articular injections of resveratrol on cartilage and synovium have been 
studied in a rabbit model of OA [169]. Resveratrol reduces cartilage tissue destruction and may protect 
cartilage against the development of experimentally induced OA. 
There is increasing evidence to show that resveratrol may act on the sirtuin system. The silent 
information regulator (SIR) genes (sirtuins) comprise a highly conserved family of proteins. SirT1, the 
first member of the sirtuin family, is an enzyme that deacetylates proteins that contribute to cellular 
regulation (reaction to stressors, longevity). Two recent review articles have examined the published 
research on resveratrol’s effects on the expression and function of sirtuins [185]. These papers also 
discuss the dietary, lifestyle, and environmental factors that influence sirtuin activity, especially dietary 
activators like resveratrol. 
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15. Clinical Trials of Other Phytochemical Based Products Approved as Medical Foods 
Limbrel [186] is a prescription medical food product for the clinical dietary management of the 
metabolic processes of osteoarthritis (OA). Limbrel was developed and formulated specifically for 
patients with OA. Although it is not a NSAID, nor a COX-2 selective inhibitor, it is proposed to 
function as an anti-oxidant as well as being a dual inhibitor of the cyclooxygenase (COX) and 
lipoxygenase (LOX) enzymes of arachidonic acid metabolism. Limbrel is manufactured according to 
FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP). It contains 
flavocoxid, a proprietary blend of natural ingredients from phytochemical food source materials. 
Flavocoxid is comprised primarily of the flavonoids such as baicalin and catechin. These or similar 
ingredients can be found in common foods such as soy, peanuts, cauliflower, kale, apples, apricots, 
cocoa and green tea. The fact that these and similar ingredients have been widely researched and used 
in medicinal products in other countries also supports biacalin and catechin’s safety and effectiveness. 
Limbrel provides levels of these flavonoids needed to meet the distinctive nutritional requirements of 
people with osteoarthritis and cannot be obtained through simply changing the diet. A recently 
conducted clinical trial of Limbrel (ClinicalTrials.gov [156] Identifier: NCT00928837) [187] has 
shown Limbrel to be effective in safely managing the unique nutritional needs of OA with side effects 
comparable to placebo. The Primary and Secondary Outcome Measures were to compare the efficacy, 
safety, quality of life and economic impact of Limbrel compared to the NSAID Naproxen and placebo. 
16. Concluding Remarks 
Nutrigenomics is an exciting area of research that holds much promise for the development of novel 
therapeutic strategies for the treatment of inflammatory diseases. However, wider acceptance of 
nutritional intervention, dietary supplements and nutraceuticals by medical practitioners arthritis 
patients and the scientific research community will require multi-disciplinary approaches that combine 
original hypothesis driven research with well-designed basic, clinical and epidemiological studies. The 
published data supporting the anti-inflammatory and anti-catabolic effects of curcumin and resveratrol 
and their synergistic activity is quite robust. Recent work has shown that curcumin and resveratrol 
protect chondrocytes from the catabolic actions of IL-1β including MMP-3 up-regulation, inhibition of 
collagen type II and down-regulation of β1-integrin expression. These phytochemicals can blocks  
IL-1β-induced proteoglycan degradation, AP-1/NF-κB signaling, chondrocyte apoptosis and activation 
of caspase-3. Therefore phytochemicals may be a beneficial complementary treatment for OA. 
However, more basic research is required to understand the absorption and bioavailability of these 
compounds and gain a deeper insight into their functional effects. In addition, the basic research needs 
to be followed by well-designed and conducted clinical trials that meet the current expectations of food 
and drug agencies in Europe and North America.  
The European Food Safety Authority (EFSA) [188] based in Parma, Italy has issued new guidelines 
and proposed new scientific requirements for health claims related to the maintenance of joints and to 
the reduction of the risk of developing OA. EFSA has proposed that clinical trials of functional foods 
and nutraceuticals should be designed in new and innovative ways to demonstrate a ―beneficial 
physiological effect‖ on healthy joints. For example, new guidelines have been introduced for the 
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substantiation of health claims related to glucosamine alone or in combination with chondroitin 
sulphate and maintenance of joints [189]. According to regulation EC 1924/2006 a ―beneficial 
physiological effect‖ has specific meanings for function and disease risk claims.  
 For function claims: To maintain or to improve a function 
 For reduction of disease risk claims: To reduce a risk factor for the development of a human 
disease (not reduction of the risk of the disease)—a risk factor that may serve as a predictor 
of development of that disease 
According to these new guidelines only clinical trials designed to demonstrate a beneficial 
physiological effect on joints or a reduction in joint degradation in people without OA should be 
accepted as indicative. These guidelines present some major new challenges to the scientific and 
clinical communities. Furthermore, they create a number of opportunities for new types of clinical 
trials. Since the maintenance of a ―normal joint‖ is considered to be a beneficial physiological effect, 
possible outcomes related to joint structure and function may include changes in:  
 Joint space width on radiographs 
 Mobility 
 Stiffness 
 Joint discomfort (i.e., pain) 
Studies performed in non-diseased (including high risk) population subgroups in which the 
incidence of OA is the outcome measure could be used for substantiation of health claims relating to 
the normal maintenance of the joint. Whilst attempting to address these requirements, we need to 
discriminate between food and non-food supplements. Studies dealing with ―non-foods‖ will require a 
much more traditional pharmacological design compared to studies on ―foods‖. Clearly, addressing 
this issue requires new strategies and large scale clinical studies lasting several decades. Such new 
trials will require radical rethinking of the concept of clinical trials in the OA research community. 
Human studies appear to be central for substantiation of clinical data and study groups should be 
representative of the entire population. Hierarchy of evidence is also considered; for example 
interventional studies are of greater significance compared to observational studies and reproducibility 
of the effect much be demonstrated. In addition, demonstrating efficacy of food supplements to EFSA 
will also require data on tolerance and safety, specifically gastric tolerance, hepatotoxicity, renal 
toxicity and allergenicity. Once these important obstacles have been overcome and new clinical trials 
have been carried out, curcumin and resveratrol may become useful alternative adjuncts to the NSAIDs 
that are currently used for the treatment of OA. 
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